OncoSeer Diagnostics, Inc. (OncoSeer), a collaboration with UT Southwestern Medical Center (UTSW), is developing multimarker blood tests that diagnose and predict immune related adverse events (irAE) in oncology patients undergoing immune checkpoint inhibitor (ICI) therapy.
American Cancer Society. Cancer Facts and Figures 2022 Haslam & Prasad. JAMA Network Open 2019;2(5): e192535 Zheng etal.The Oncologist 2021; 26:e2002-2012
Shaheen Khan , Saad A. Khan, Xin Luo, Farjana J. Fattah, Jessica Saltarski, Yvonne Gloria-McCutchen , Rong Lu, Yang Xie, Quan Li, Edward Wakeland and David E. Gerber
Up to 40% of cancer patients on immune checkpoint inhibitors develop clinically significant immune-related adverse events (irAEs). The role of host immune status and function in predisposing patients to the development of irAEs remains unknown
David Hsiehchen, MD; Mary K. Watters, MD; Rong Lu, PhD; Yang Xie, PhD; David E. Gerber, MD
Toxic effects of conventional chemotherapy and molecularly targeted cancer therapies are generally well defined and occur at predictable points. By contrast, owing to their heterogeneous manifestations, unpredictable timing, and clinical overlap with other conditions, immune-related adverse events (irAE) may be more difficult to diagnose and characterize.
Shaheen Khan, Mitchell S. von Itzstein, Rong Lu, Bonnie L. Bermas, David R. Karp, Saad A. Khan, Farjana J. Fattah, Jason Y. Park, Jessica M. Saltarski, Yvonne Gloria‐McCutchen, Yang Xie, Quan‐Zhen Li, Edward K. Wakeland, David E. Gerber,
Immune checkpoint inhibitor (ICI)-induced immune-related adverse events (irAEs) may affect almost any organ system and occur at any point during therapy. Autoantibody analysis may provide insight into the mechanism, nature, and timing of these events.
Amrit S Gonugunta ,Mitchell S von Itzstein, Hong MuMosley , Farjana Fattah, J David Farrar, Angela Mobely, Sawsan Rashdan, Sunny Lai, Salman F Bhai, Bonnie L Bermas,David Karp, Quan-Zhen Li, Edward K Wakeland, David E Gerber
While immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer, associated toxicities termed immune-related adverse events (irAE) occur in a substantial proportion of patients. These autoimmune events may affect almost any organ system.
Jared Ostmeyer, Jason Y Park, Mitchell S von Itzstein, David Hsiehchen, Farjana Fattah, Mary Gwin, Rodrigo Catalan, Shaheen Khan, Prithvi Raj, Edward K Wakeland, Yang Xie, David E Gerber
Background Immune checkpoint inhibitor (ICI) therapies may cause unpredictable and potentially severe autoimmune toxicities termed immune-related adverse events (irAEs). Because T cells mediate ICI effects, T cell profiling may provide insight into the risk of irAEs.